JP2005530716A - ヒトにおける癌の治療方法 - Google Patents

ヒトにおける癌の治療方法 Download PDF

Info

Publication number
JP2005530716A
JP2005530716A JP2003579755A JP2003579755A JP2005530716A JP 2005530716 A JP2005530716 A JP 2005530716A JP 2003579755 A JP2003579755 A JP 2003579755A JP 2003579755 A JP2003579755 A JP 2003579755A JP 2005530716 A JP2005530716 A JP 2005530716A
Authority
JP
Japan
Prior art keywords
cancer
mammal
fragment
tumor
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003579755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530716A5 (enExample
Inventor
ホゥ、パトリック
ワン、グァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28675491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2005530716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2005530716A publication Critical patent/JP2005530716A/ja
Publication of JP2005530716A5 publication Critical patent/JP2005530716A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2046—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/35—Cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2003579755A 2002-03-27 2003-03-27 ヒトにおける癌の治療方法 Pending JP2005530716A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36843802P 2002-03-27 2002-03-27
PCT/US2003/009707 WO2003082212A2 (en) 2002-03-27 2003-03-27 Method for treating cancer in humans

Publications (2)

Publication Number Publication Date
JP2005530716A true JP2005530716A (ja) 2005-10-13
JP2005530716A5 JP2005530716A5 (enExample) 2006-01-12

Family

ID=28675491

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003579755A Pending JP2005530716A (ja) 2002-03-27 2003-03-27 ヒトにおける癌の治療方法

Country Status (6)

Country Link
US (2) US20050063947A1 (enExample)
EP (1) EP1589990B1 (enExample)
JP (1) JP2005530716A (enExample)
AU (1) AU2003226141A1 (enExample)
CA (1) CA2481304A1 (enExample)
WO (1) WO2003082212A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514601A (ja) * 2002-06-07 2006-05-11 ザイモジェネティクス インコーポレイティッド ガンおよびその他の治療用途におけるｉｌ−２１の使用方法
WO2010095463A1 (ja) 2009-02-20 2010-08-26 有限会社メイショウ 免疫増強組成物及びそれを製造する方法
JP2012070742A (ja) * 2005-04-18 2012-04-12 Novo Nordisk As Ｉｌ−２１変異体
JP2020536533A (ja) * 2017-09-26 2020-12-17 ハンジョウ コンバート カンパニー, リミテッドHangzhou Converd Co., Ltd. 腫瘍および／または癌の処置のための医薬のための単離された組換え体腫瘍溶解性ワクシニアウイルス、医薬組成物、およびそれらの使用

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610286B2 (en) 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
US7122632B2 (en) 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
US20050063947A1 (en) * 2002-03-27 2005-03-24 Patrick Hwu Method for treating cancer in humans
AU2003251633A1 (en) 2002-07-01 2004-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Il-21 as a regulator of immunoglobin production
AU2003302250B2 (en) 2002-12-13 2009-08-27 Zymogenetics, Inc. IL-21 production in prokaryotic hosts
ZA200507235B (en) * 2003-03-21 2007-03-28 Wyeth Corp Treating immunological disorders using agonists of interleukin-21/interleukin-21 receptor
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1680138B1 (en) * 2003-10-17 2013-07-17 Novo Nordisk A/S Combination therapy
EP2633866A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
US7993919B2 (en) 2003-11-19 2011-08-09 The United States Of America As Represented By The Department Of Health And Human Services Method of inducing memory B cell development and terminal differentiation
MX2007015039A (es) * 2005-06-06 2008-01-24 Novo Nordisk As Composiciones de il-21 estabilizadas.
GB0519303D0 (en) * 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
PL1963369T3 (pl) 2005-11-28 2013-10-31 Zymogenetics Inc Antagoniści IL-21
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
US8211420B2 (en) 2006-12-21 2012-07-03 Novo Nordisk A/S Interleukin-21 variants with altered binding to the IL-21 receptor
WO2008112543A2 (en) * 2007-03-09 2008-09-18 Wyeth Rat, rabbit, and cynomolgus monkey il-21 and il-22 nucleotide and polypeptide sequences
BR112012021576A2 (pt) 2010-02-26 2016-10-25 Novo Nordisk As composições estáveis contendo anticorpo.
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
ES2989085T3 (es) 2011-01-18 2024-11-25 Bioniz Therapeutics Inc Composiciones para modular la actividad de citoquinas gamma-c
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
GB201405834D0 (en) * 2014-04-01 2014-05-14 Univ London Queen Mary Oncolytic virus
AU2015323944B2 (en) * 2014-10-01 2018-11-29 Inovio Pharmaceuticals, Inc. Vaccines having an antigen and interleukin-21 as an adjuvant
US10618944B2 (en) 2015-02-27 2020-04-14 Saint Louis University Tumor suppressor SALL1 as a therapeutic agent for treating cancer
DK3359556T3 (en) 2015-10-09 2021-08-30 Bioniz Llc Modulering af gamma-c-cytokinaktivitet
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
AU2018251898A1 (en) 2017-04-13 2019-10-31 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
AU2019359890B2 (en) 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3976182A4 (en) 2019-05-03 2023-01-18 Bioniz, LLC MODULATION OF THE EFFECTS OF GAMMA CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ATE222291T1 (de) * 1992-03-13 2002-08-15 Organon Teknika Bv Epstein-barr-virus verwandte peptide und nukleinsäuresegmenten
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
EP1082433A4 (en) * 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukins 21 and 22
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US6312924B1 (en) * 1999-03-18 2001-11-06 Zymogenetics, Inc. Murine interferon-α
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
DE60125543T2 (de) * 2000-04-05 2007-10-04 Zymogenetics, Inc., Seattle Löslicher zytokinrezeptor zalpha11
US6759045B2 (en) * 2000-08-08 2004-07-06 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia
WO2002072796A2 (en) * 2001-03-12 2002-09-19 Cellcure Aps Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity
DK1432431T3 (en) * 2001-10-04 2017-07-10 Genetics Inst Llc Methods and compositions for modulating interleukin-21 activity
US20050063947A1 (en) * 2002-03-27 2005-03-24 Patrick Hwu Method for treating cancer in humans

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006514601A (ja) * 2002-06-07 2006-05-11 ザイモジェネティクス インコーポレイティッド ガンおよびその他の治療用途におけるｉｌ−２１の使用方法
JP2012070742A (ja) * 2005-04-18 2012-04-12 Novo Nordisk As Ｉｌ−２１変異体
WO2010095463A1 (ja) 2009-02-20 2010-08-26 有限会社メイショウ 免疫増強組成物及びそれを製造する方法
KR20110118724A (ko) 2009-02-20 2011-10-31 유겐가이샤 메이쇼 면역 증강 조성물 및 그것을 제조하는 방법
US8454979B2 (en) 2009-02-20 2013-06-04 Meisho Co., Ltd. Immunopotentiating composition and process for producing same
JP2020536533A (ja) * 2017-09-26 2020-12-17 ハンジョウ コンバート カンパニー, リミテッドHangzhou Converd Co., Ltd. 腫瘍および／または癌の処置のための医薬のための単離された組換え体腫瘍溶解性ワクシニアウイルス、医薬組成物、およびそれらの使用
JP7248325B2 (ja) 2017-09-26 2023-03-29 ハンジョウ コンバート カンパニー，リミテッド 腫瘍および／または癌の処置のための医薬のための単離された組換え体腫瘍溶解性ワクシニアウイルス、医薬組成物、およびそれらの使用
JP2023071953A (ja) * 2017-09-26 2023-05-23 ハンジョウ コンバート カンパニー，リミテッド 単離された組換え体腫瘍溶解性ワクシニアウイルスとｎｋ細胞を含む治療薬、その使用およびそれを適用したキット
JP7564572B2 (ja) 2017-09-26 2024-10-09 ハンジョウ コンバート カンパニー，リミテッド 単離された組換え体腫瘍溶解性ワクシニアウイルスとｎｋ細胞を含む治療薬、その使用およびそれを適用したキット

Also Published As

Publication number Publication date
WO2003082212A3 (en) 2005-07-14
US20050063947A1 (en) 2005-03-24
US20100135958A1 (en) 2010-06-03
EP1589990A4 (en) 2008-03-05
EP1589990A2 (en) 2005-11-02
EP1589990B1 (en) 2012-11-14
WO2003082212A2 (en) 2003-10-09
CA2481304A1 (en) 2003-10-09
AU2003226141A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
EP1589990B1 (en) Il-21 for use in treating cancer
JP4787439B2 (ja) 免疫調節因子であるｂａｆｆレセプター（ｂｃｍａ）
JP4842128B2 (ja) 新規多機能性サイトカイン
JP4880060B2 (ja) 新規多機能性サイトカイン
EP4656653A2 (en) Tethered interleukin-15 and interleukin-21
US8298790B2 (en) Methods for effectively coexpressing IL-12 and IL-23
WO2003106682A1 (ja) Ｈｌａ−ａ２４拘束性癌抗原ペプチド
KR20170094341A (ko) 인터류킨 15 단백질 복합체 및 그의 용도
KR20180088458A (ko) 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
JP2022548364A (ja) 免疫療法のエンハンサーとして有用なｉｌ－１０／ｆｃ融合タンパク質
CZ20011521A3 (cs) Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek
ES2416510T3 (es) Uso de una citocina capaz de unirse a IL 18BP y de inhibir la actividad de una segunda citocina
KR20060129393A (ko) ＨＬＡ－Ａ2402-제한 Ｅｐ－ＣＡＭ 특이적 ＣＴＬ에인식되는 에피토프/펩티드 및 그 용도
KR101949186B1 (ko) 면역 유도제
JP4839434B2 (ja) ｐ２８分子またはその遺伝子を含む医薬製剤
WO2006032525A2 (en) Combinational therapy for treating cancer
KR102829639B1 (ko) c-Met의 에피토프를 포함하는 암 백신 및 이의 용도
KR102545373B1 (ko) 면역 유도제
WO2007081301A2 (en) Methods and compositions related to the identification of a novel il-12 inducing protein isolated from toxoplasma gondii
KR102520880B1 (ko) 면역유도제
TW200908997A (en) Treatment of cellular proliferative disorders
KR102676438B1 (ko) 면역 유도제
WO2007018229A1 (ja) 成人ｔ細胞白血病治療
JP2008527986A (ja) 炎症及び／又は自己免疫疾患における可溶性ｃｄ１６４の使用
Thomas et al. Dendritic Cell-Induced Activation of

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20050905

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060320

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090602

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091104